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year: the lowest in the youngest age group and the highest 
in the oldest. Intracranial haemorrhage was seen at an unac-
ceptable rate (0.6–0.7/year) in all age groups. Therefore, the 
authors conclude that the use of mechanical AVR below the 
age of 60 years is associated with a similar rate of intracra-
nial bleeding as seen in older patients.
This report shows the deleterious effect of over-anticoag-
ulation in many patients with a low-risk mechanical aortic 
prosthesis. Bleeding on VKA is highly dependent on INR 
monitoring. Since 2007 international guidelines recommend 
a target INR of 2.5 in carriers of a mechanical aortic valve 
without risk factors such as atrial fibrillation. The St. Jude 
Medical prosthesis in the aortic position, which was used in 
half of the patients, is considered a valve with a low throm-
botic risk and only very few of the patients under 60 years 
of age had atrial fibrillation. Therefore, the bleeding—espe-
cially intracranial bleeding—encountered in this cohort is 
unacceptable. Of course, this knowledge was not available 
at the time the first patients were included in this cohort; 
however, already in 1996 the Leiden group published the 
low thrombosis rate in this type of valve [4]. And in 2006 
and 2007 the American [5] and European [6] guidelines 
became available and have not changed on this topic since 
then (Fig. 1) [7]. But it was not until 2010 that the Nether-
lands Federation of Thrombosis Clinics mentioned, in their 
yearly report, the existence of a differentiated approach for 
patients with artificial heart valves [8]. This explains why 
the rate of major bleeding described in this cohort did not 
seem to drop over the years.
Thus, knowledge of the guidelines is essential in the man-
agement of patients in general, but of this group of patients 
with a delicate balance between thrombosis and bleeding in 
particular.
Heart valve surgery has been one of the great leaps forward 
in the management of heart disease in the last 60 years. 
Thanks to technical developments, artificial heart valves 
were constructed that prove to be competent and durable. 
Besides the risk of infective endocarditis, thromboembolism 
from the foreign body structures of the prosthesis remains 
a major problem, which can be effectively reduced, but not 
annihilated by the use of oral anticoagulants. For nearly all 
patients on oral anticoagulants, bleeding is the most com-
mon problem. The only available and proven effective oral 
anticoagulants for carriers of mechanical heart valve pros-
thesis are the vitamin-K antagonists (VKA). They need 
intensive monitoring of the anticoagulation status through 
the dense network of thrombosis clinics in the Netherlands. 
Recently, non-VKA direct-acting oral anticoagulants were 
introduced, which are safer and more effective than VKA 
in stroke prevention in atrial fibrillation [1]. They have also 
been tested in patients undergoing mechanical heart valve 
replacement and in those with recent implantation, but here 
they failed in efficacy and safety in comparison with VKA 
[2]. Thus, VKA remains the standard of anticoagulation care 
for patients carrying artificial heart valves.
In the today’s issue of the Netherlands Heart Journal the 
results of a retrospective registry of mechanical aortic valve 
replacement (AVR) are presented by Swinkels et al. [3]. 
Data were collected in a single-centre experience and have a 
very long follow-up. Bleeding complications were collected 
in relation to age (< 60, 60–65 and > 65 years) at the time of 
surgery. The authors found a high rate of major bleeding per 
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Fig. 1 2007 recommendations of the European Society of Cardiology 
on the INR in the anticoagulant management of patients with mechani-
cal heart valve prosthesis. [6]
 
